{"nctId":"NCT02525523","briefTitle":"Efficacy of Alicaforsen in Pouchitis Patients Who Have Failed to Respond to at Least One Course of Antibiotics","startDateStruct":{"date":"2015-12-03","type":"ACTUAL"},"conditions":["Pouchitis"],"count":138,"armGroups":[{"label":"Alicaforsen","type":"EXPERIMENTAL","interventionNames":["Drug: Alicaforsen"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Alicaforsen","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Written informed consent;\n2. Male or female subjects, 18 years of age who have undergone an IPAA for UC\n3. History of pouchitis\n4. Overall PDAI score \\> 7\n5. Must have Chronic Antibiotic Refractory Pouchitis\n\nExclusion Criteria:\n\n1. Lack of effective contraception\n2. Women who are pregnant or breastfeeding;\n3. Strong analgesia NSAID use\n4. Change in dose of the following permitted meds during screening and study: oral 5-aminosalicylate (5 ASA), Oral steroids,, Immunosuppressant therapy.\n5. Rectal products\n6. Biological agents: Anti-tumour necrosis factor (anti - TNF) therapy and / or vedolizumab; are not permitted within 8 weeks of the Screening Visit.\n7. All other agents targeted to pouchitis, including experimental agents, must have been discontinued at least 8 weeks prior to the Screening Visit, or for a period equivalent to 5 half-lives (t½) of the agent (whichever is longer)\n8. Anal sphincter dysfunction\n9. Infections to cytomegalovirus or Clostridium Difficile\n10. Other GI pathology (inc. intestinal malabsorption, pancreatic maldigestion etc) and differential diagnoses\n11. Clinically significant and/or persistent illness; which in the investigators opinion, would exclude entry into the trial","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Proportion of Patients With Endoscopic Remission","description":"The group of patients with an improvement in their endoscopic score between screening and week 10 as shown by an reduced modified MAYO score. Remission is defined as absence of friability and ulceration, represented by a score of ≤1.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"PRIMARY","title":"Proportion of Patients With a Reduction in Relative Stool Frequency","description":"Group of patients with a lowering of stool frequency from baseline to week 10, where the subject's stool frequency is represented by a MAYO subscore of ≤1 at week 10.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":69},"commonTop":["Abdominal pain","Pouchitis","Nasopharyngitis","Anorectal discomfort","Diarrhoea"]}}}